Wegovy®, semaglutide 2.4 mg, is a glucagon-like peptide-1 analogue that has been approved by the National Institute for Health and Care Excellence (NICE) for the treatment of adults with obesity in the National Health Service (NHS). In this review, we provide a reflection on NICE TA875 and its implementation in the NHS.
No takes yet. Share an insight, caveat, or question.
Kahal et al. (2024) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: